Morepen Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Morepen Laboratories is de winst gegroeid met een gemiddeld jaarlijks percentage van 11.3%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.4%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 13.6% per jaar. Het rendement op eigen vermogen van Morepen Laboratories is 11.9%, en het heeft een nettomarge van 7.4%.

Belangrijke informatie

11.3%

Groei van de winst

7.8%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	17.5%
Inkomstengroei	13.6%
Rendement op eigen vermogen	11.9%
Nettomarge	7.4%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09

Recent updates

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Aug 20

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Jul 05

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Jun 13

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Apr 23

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Nov 23

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Aug 10

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 21

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Apr 05

Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 07

Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Jan 21

Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Jan 03

Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Dec 16

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Nov 28

Opbrengsten en kosten

Hoe Morepen Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:MOREPENLAB Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	17,748	1,313	2,017	0
30 Jun 24	17,571	1,177	1,998	0
31 Mar 24	17,019	962	1,935	0
31 Dec 23	16,422	761	2,127	0
30 Sep 23	15,433	531	1,958	0
30 Jun 23	15,238	477	2,884	0
31 Mar 23	14,220	387	1,654	0
31 Dec 22	14,270	428	1,800	0
30 Sep 22	14,765	553	1,843	0
30 Jun 22	14,721	768	2,604	0
31 Mar 22	15,558	1,017	1,724	0
31 Dec 21	14,743	1,161	1,809	0
30 Sep 21	13,854	1,184	1,589	0
30 Jun 21	13,295	1,082	2,092	0
31 Mar 21	11,980	971	1,407	0
31 Dec 20	11,136	814	1,345	0
30 Sep 20	10,380	684	1,279	0
30 Jun 20	9,183	453	1,678	0
31 Mar 20	8,584	336	1,143	0
31 Dec 19	8,731	331	1,161	0
30 Sep 19	8,530	312	1,118	0
30 Jun 19	8,117	340	1,474	0
31 Mar 19	7,714	288	995	0
31 Dec 18	7,258	252	980	0
30 Sep 18	6,672	267	879	0
30 Jun 18	6,436	308	841	0
31 Mar 18	6,101	296	807	0
31 Mar 17	5,991	236	739	0
31 Mar 16	4,861	128	616	0
31 Mar 15	4,014	21	517	0
31 Mar 14	3,670	-28	807	4

Kwaliteitswinsten: MOREPENLAB heeft een hoog niveau van non-cash earnings.

Groeiende winstmarge: De huidige netto winstmarges (7.4%) MOREPENLAB } zijn hoger dan vorig jaar (3.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van MOREPENLAB is de afgelopen 5 jaar met 11.3% per jaar gegroeid.

Versnelling van de groei: De winstgroei van MOREPENLAB over het afgelopen jaar ( 147.1% ) overtreft het 5-jarig gemiddelde ( 11.3% per jaar).

Winst versus industrie: De winstgroei MOREPENLAB over het afgelopen jaar ( 147.1% ) overtrof de Pharmaceuticals -sector 20.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 11.9% ) van MOREPENLAB wordt als laag beschouwd.

Morepen Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.42 in 2Q 2024)

Morepen Laboratories Limited to Report Q2, 2025 Results on Nov 11, 2024

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Morepen Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.42 in 2Q 2024)

Morepen Laboratories Limited to Report Q2, 2025 Results on Nov 11, 2024

Morepen Laboratories Limited Announces Board Cessation

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

Investor sentiment improves as stock rises 21%

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2024

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Investor sentiment improves as stock rises 19%

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Morepen Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Morepen Laboratories Limited has filed a Follow-on Equity Offering.

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹1.88 (vs ₹0.77 in FY 2023)

Morepen Laboratories Limited to Report Q4, 2024 Results on May 21, 2024

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 15%

Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API

Third quarter 2024 earnings released: EPS: ₹0.63 (vs ₹0.15 in 3Q 2023)

Investor sentiment improves as stock rises 17%

Morepen Laboratories Limited to Report Nine Months, 2024 Results on Jan 31, 2024

Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel

Investor sentiment improves as stock rises 17%

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings released: EPS: ₹0.42 (vs ₹0.33 in 2Q 2023)

Morepen Laboratories Limited to Report Q2, 2024 Results on Nov 02, 2023

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Morepen Laboratories Limited, Annual General Meeting, Sep 28, 2023

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

First quarter 2024 earnings released: EPS: ₹0.29 (vs ₹0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: ₹0.77 (vs ₹2.26 in FY 2022)

Morepen Laboratories Limited to Report Q4, 2023 Results on May 16, 2023

Third quarter 2023 earnings released: EPS: ₹0.15 (vs ₹0.48 in 3Q 2022)

Morepen Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023

Investor sentiment improved over the past week

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹0.33 (vs ₹0.83 in 2Q 2022)

Morepen Laboratories Limited to Report Q2, 2023 Results on Nov 10, 2022

Investor sentiment deteriorated over the past week

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Morepen Laboratories Limited, Annual General Meeting, Sep 27, 2022

Insufficient new directors

First quarter 2023 earnings released: EPS: ₹0.12 (vs ₹0.68 in 1Q 2022)

Morepen Laboratories Limited to Report Q1, 2023 Results on Jul 29, 2022

Morepen Laboratories Limited Announces Resignation of Anju Suri as Director (Non-Executive, Non-Independent)

Morepen Laboratories Limited announced that it has received INR 1.1465201 billion in funding from a group of investors

Full year 2022 earnings released: EPS: ₹2.26 (vs ₹2.16 in FY 2021)

Investor sentiment improved over the past week

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Investor sentiment improved over the past week

Morepen Laboratories Limited Announces Cessation of Arun Kumar Sinha as Whole Time Director

Morepen Laboratories Limited announced that it expects to receive INR 1.1465201 billion in funding from a group of investors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹0.83 (vs ₹0.60 in 2Q 2021)

Less than half of directors are independent

Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹0.68 (vs ₹0.43 in 1Q 2021)

Investor sentiment improved over the past week

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Morepen Laboratories Limited announced that it expects to receive INR 4.3336 billion in funding from Liquid Holdings Pvt Ltd, Corinth Investment Holdings AG

Investor sentiment improved over the past week